Therapy Detail

Therapy Name INCB039110 + INCB050465
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
INCB050465 PIK3CD inhibitor 24 INCB050465 inhibits PI3K-delta, blocking activation of AKT signaling pathway and leading to apoptosis of PIK3CD expressing tumor cells (NCI Drug Dictionary).
Itacitinib INCB039110 JAK1 Inhibitor 8 Itacitinib (INCB039110) is a selective inhibitor of Janus kinase 1 (JAK1), which may inhibit cell proliferation (PMID: 25605813).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown diffuse large B-cell lymphoma not applicable INCB039110 + INCB050465 Preclinical - Cell line xenograft Actionable In a preclinical study, INCB050465 and INCB039110 combination treatment inhibited proliferation of diffuse large B-cell lymphoma cell lines in culture and induced tumor regression in xenograft models ( Cancer Res August 1, 2015 75; 2671 ). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02018861 Phase I Itacitinib INCB039110 + INCB050465 Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide INCB050465 A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting
NCT02559492 Phase I INCB039110 + INCB024360 INCB039110 + INCB050465 INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting